alejandro.sanabria@americaneagle.com, Author at CureDuchenne

CureDuchenne Founder and CEO Debra Miller is an EY Entrepreneur of the Year 2014 Award Finalist in Orange County

May 12, 2014

CureDuchenne is pleased to announce that Debra Miller, founder and CEO of CureDuchenne, is a finalist for the EY Entrepreneur Of The YearÌ¢Û_å¢ 2014 Award in Orange County. The awards program recognizes entrepreneurs who demonstrate excellence and extraordinary success in such areas as innovation, financial performance and personal commitment to their businesses and communities. Miller was selected as a finalist from nearly 80 applications by a panel of independent judges. Award winners will be announced at a special gala event on June 4, 2014 at The St. Regis Resort in Dana Point.

Sarepta to Host Webinar Tuesday, May 13

May 6, 2014

Sarepta Therapeutics, Inc. will host a webcast and conference call for the Duchenne muscular dystrophy (DMD) community on Tuesday, May 13, 2014, beginning at 11:00 am EDT (8:00 am […]

Prosensa Provides Update on Drisapersen

May 1, 2014

Re-dosing plans are underway and 96-week data from an open-label extension study of drisapersen for the treatment of DMD presented at the American Academy of Neurology (AAN) Leiden, The Netherlands, […]

Prosensa actively working on re-dosing drisapersen and regulatory path forward

April 29, 2014

CureDuchenne is pleased to share the following information from Prosensa. Dear Patient Group Representative, As we continue to receive all of the materials, data and know-how from GSK regarding […]

Sarepta Therapeutics to Host Webcast and Conference Call for the Duchenne Muscular Dystrophy Community on May 13, 2014

April 28, 2014

April 28, 2014, 8:32 a.m. EDT CAMBRIDGE, Mass., Apr 28, 2014 (BUSINESS WIRE) — Sarepta Therapeutics, Inc. /quotes/zigman/10874508/delayed/quotes/nls/srpt SRPT +1.17% , a developer of innovative RNA-based therapeutics, will host a webcast and conference […]

Sarepta to File Eteplirsen NDA by Year End

April 21, 2014

Summary from Seeking Alpha Based on updated guidance from the FDA regarding an early approval pathway for eteplirsen, Sarepta Therapeutics (SRPT) plans to file an NDA by the end of 2014. The […]

Champions to CureDuchenne Newport Beach Gala Raises More Than $360,000 to Fund Duchenne Muscular Dystrophy Research

April 2, 2014

CureDuchenne, a nonprofit that raises awareness and funds research to find a cure for Duchenne muscular dystrophy, held its annual Champions to CureDuchenne Newport Beach Gala on March 29 at the Balboa Bay Club & Resort. More than 250 guests attended the gala that celebrated CureDuchenneÌ¢âÂã¢s 10 years of successfully advancing Duchenne research. The event raised more than $360,000 that will fund promising Duchenne research.

Eteplirsen, Drisapersen, the FDA and Dedicated Duchenne Moms

March 26, 2014

Congratulations to the Race to Yes organizers (Tracy Seckler, Jenn McNary, Christine McSherry, Mindy Leffler, and many others) and the Duchenne community for their passionate and successful campaign to petition […]

Drisapersen Update with Prosensa

March 19, 2014

Prosensa will present a status update on Drisapersen and its follow-on compounds in a patient focused webinar hosted by United Parent Projects Muscular Dystrophy (UPPMD) on Tuesday, March 25 at […]